OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Grünwald on Tumor Burden Outcomes From the CLEAR Trial in Advanced RCC

August 29th 2024

Viktor Grünwald, MD, PhD, discusses differences in tumor burden between patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab vs sunitinib.

Dr Hantel on Eligibility Criteria Associated With Racial/Ethnic Disparities in Clinical Trial Enrollment in AML

August 29th 2024

Andrew Hantel, MD, discusses eligibility criteria associated with racial and ethnic disparities in clinical trial participation in acute myeloid leukemia.

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

August 29th 2024

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Daver on the Evolution of Survivorship and Treatment Outcomes in AML

August 29th 2024

Naval G. Daver, MD, discusses the evolution of survivorship in patients with acute myeloid leukemia.

Dr Olivares on Considerations for Managing Prostate Cancer in the Community Setting

August 29th 2024

Ruben Olivares, MD, discusses considerations for managing prostate cancer in the community setting, particularly regarding early detection and screening.

Dr Banerjee on Various Dosing Schedules of Bispecific Antibodies in Myeloma

August 29th 2024

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

Dr Vahdat on the Role of Copper Depletion in Reducing Metastatic Disease Risk in TNBC

August 28th 2024

Linda Vahdat, MD, MBA, discusses the role of copper depletion in reducing the risk of metastatic disease development in triple-negative breast cancer.

Dr Liao on the Value of Molecular Testing in Biliary Tract Carcinoma

August 28th 2024

Chih-Yi Liao, MD, discusses the value of molecular testing in biliary tract carcinoma.

Dr Strickler on the Significance of Fruquintinib for Patients With Refractory mCRC

August 28th 2024

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Dr Shadman on the Impact of Early Dose Reduction on Real-World Outcomes With Ibrutinib in CLL/SLL

August 28th 2024

Mazyar Shadman, MD, MPH, discusses real-world outcomes following early dose adjustments of first-line ibrutinib in CLL/SLL.

Dr McGregor on the Investigation of Abemaciclib Monotherapy in ccRCC

August 28th 2024

Bradley McGregor, MD, discusses the rationale for investigating abemaciclib monotherapy in patients with clear cell renal cell carcinoma.

Dr Guerra on the Implications of a Study on Prostate Cancer Screening in Diverse Populations

August 28th 2024

Carmen Guerra, MD, MSCE, FACP, discusses the implications of research into the rates of prostate cancer screening in a population of diverse men.

Dr Kamdar on the Benefit of Liso-Cel Therapy Across Lymphoma Subgroups

August 28th 2024

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Dr Cigliola on Potential Implications of the SURE-01 and SURE-02 Trials in MIBC

August 27th 2024

Antonio Cigliola, MD, discusses potential clinical implications of data from the phase 2 SURE-01 and SURE-02 trials in MIBC.

Dr Forsyth on the Potential Utility of Intrathecal cDC1s in Leptomeningeal Disease

August 27th 2024

Peter Forsyth, MD, discusses the evaluation of intrathecal dendritic cells for patients with TNBC/HER2-positive leptomeningeal disease.

Dr Daver on the Potential Role of MRD Assessment in AML Treatment

August 27th 2024

Naval G. Daver, MD, discusses the potential role of minimal residual disease assessments in acute myeloid leukemia.

Dr El-Khoueiry on Immune Suppression in Advanced HCC After Checkpoint Inhibitors

August 27th 2024

Anthony B. El-Khoueiry, MD, discusses immune suppression in advanced hepatocellular carcinoma post-checkpoint inhibitor therapy.

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

August 27th 2024

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Dr Townsend on the Future Analysis of Prostate Cancer Driver Mutations Using Neoplasm Tissue Samples

August 27th 2024

Jeffrey P. Townsend, PhD, discusses analysis of prostate cancer driver mutations using early neoplasm tissue samples.

Dr Yekedüz on the Importance of the KEYNOTE-564 Trial in Adjuvant ccRCC

August 27th 2024

Emre Yekedüz, MD, discusses a case study on a patient with clear cell renal cell carcinoma, highlighting adjuvant treatment options for this individual.